STAT+: 23andMe finds genetic changes appear to help predict response to GLP-1 drugs for weight loss
Why it matters: Genetic insights from 23andMe could help 23andMe Total Health users understand their potential GLP-1 drug response.
- 23andMe Research Institute, led by senior author Adam Auton, found that changes in two specific genes predict substantial weight loss and side effects from GLP-1 drugs.
- The findings, published in Nature, demonstrate a genetic role in GLP-1 efficacy and side effects, according to Auton.
- Outside researchers were impressed but doubted the immediate impact of these genetic results on patient care, despite their scientific intrigue.
- Consumers using 23andMe's Total Health platform will gain access to information about these genes and their predicted GLP-1 responses.
23andMe researchers have identified specific genetic variations that may predict a patient's response to GLP-1 weight loss drugs, influencing both efficacy and the likelihood of experiencing nausea or vomiting. While outside experts acknowledge the intriguing "proof of concept," they remain skeptical about the immediate impact on patient care, despite 23andMe making this information available to its Total Health platform users.
